LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

Search

Simulations Plus Inc

Slēgts

SektorsVeselības aprūpe

18.75 -2.29

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

18.74

Max

18.91

Galvenie mērījumi

By Trading Economics

Ienākumi

67M

-681K

Pārdošana

-2.9M

17M

P/E

Sektora vidējais

48.528

78.892

EPS

-0.034

Dividenžu ienesīgums

0.48

Peļņas marža

-3.9

Darbinieki

212

EBITDA

327K

5.3M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+9.28% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.48%

2.38%

Nākamie ieņēmumi

2026. g. 8. janv.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

45M

390M

Iepriekšējā atvēršanas cena

21.04

Iepriekšējā slēgšanas cena

18.75

Ziņu noskaņojums

By Acuity

50%

50%

156 / 374 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 24. dec. 21:41 UTC

Iegādes, apvienošanās, pārņemšana

Nvidia to Buy Chip-Designer Groq for $20 Billion, CNBC Reports

2025. g. 26. dec. 20:22 UTC

Tirgus saruna

Oil Loses Ground On Russia-Ukraine Peace Efforts -- Market Talk

2025. g. 26. dec. 20:13 UTC

Tirgus saruna

U.S. Natural Gas Gains on Colder Weather Outlook -- Market Talk

2025. g. 26. dec. 19:24 UTC

Iegādes, apvienošanās, pārņemšana

Nvidia's Groq Deal Is an Instagram Moment -- With 1 Big Risk -- Barrons.com

2025. g. 26. dec. 17:45 UTC

Tirgus saruna

U.S. Diesel Down on Lower Crude Prices, Freight-Sector Lull -- Market Talk

2025. g. 26. dec. 15:52 UTC

Tirgus saruna

Oil Futures Turn Lower After Steady Start -- Market Talk

2025. g. 26. dec. 14:58 UTC

Tirgus saruna

Silver, Gold Reach New Highs Amid Geopolitical Tension -- Market Talk

2025. g. 26. dec. 14:41 UTC

Tirgus saruna

U.S. Natural Gas Futures Look to End Week Higher -- Market Talk

2025. g. 26. dec. 14:28 UTC

Tirgus saruna

Dollar Indexes Flat as Yen Rally Wanes -- Market Talk

2025. g. 26. dec. 13:47 UTC

Tirgus saruna

Oil Futures Steady in Thin Holiday Trade -- Market Talk

2025. g. 26. dec. 07:22 UTC

Tirgus saruna

Comex Gold Futures' Strong Bullish Momentum in Play, Chart Shows -- Market Talk

2025. g. 26. dec. 05:03 UTC

Tirgus saruna

Malaysian Ringgit Likely to Face Pressure From Dollar Strength in 1Q -- Market Talk

2025. g. 26. dec. 03:38 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 26. dec. 03:38 UTC

Tirgus saruna

Korean Won Strengthens, Supported by Verbal Interventions -- Market Talk

2025. g. 26. dec. 02:44 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 26. dec. 02:44 UTC

Tirgus saruna

Singapore Dollar Weakens Slightly on Likely Position Adjustments -- Market Talk

2025. g. 26. dec. 01:39 UTC

Tirgus saruna

China's Central Bank Signals Possibility of Easing Policy in Coming Months -- Market Talk

2025. g. 26. dec. 01:14 UTC

Tirgus saruna

Oil Edges Higher Amid Geopolitical Tensions -- Market Talk

2025. g. 26. dec. 00:34 UTC

Tirgus saruna

Yen Mostly Weakens Amid Risk-on Sentiment -- Market Talk

2025. g. 26. dec. 00:15 UTC

Tirgus saruna

Nikkei Gains 0.6%, Led by Tech, Videogame Stocks -- Market Talk

2025. g. 25. dec. 23:42 UTC

Tirgus saruna

Nikkei May Trade in Range; Yen in Focus -- Market Talk

2025. g. 25. dec. 23:40 UTC

Tirgus saruna

Gold Edges Higher Amid Geopolitical Risks -- Market Talk

2025. g. 25. dec. 00:20 UTC

Iegādes, apvienošanās, pārņemšana

Nike Climb Boosts Dow, S&P 500 -- 2nd Update

2025. g. 24. dec. 22:22 UTC

Iegādes, apvienošanās, pārņemšana

Nvidia, Groq Strike AI Tech Licensing Deal -- Barrons.com

2025. g. 24. dec. 21:26 UTC

Iegādes, apvienošanās, pārņemšana

Nvidia to Buy Chip-Designer Groq for $20B, CNBC Reports

2025. g. 24. dec. 19:35 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 24. dec. 19:35 UTC

Tirgus saruna

Treasury Yields Decline Ahead of Christmas -- Market Talk

2025. g. 24. dec. 19:09 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Global Equities Roundup: Market Talk

2025. g. 24. dec. 19:09 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

ServiceNow's Armis Acquisition Shouldn't Fuel Fears That Seat-Based Model Threatened -- Market Talk

2025. g. 24. dec. 19:06 UTC

Tirgus saruna

Oil Futures Little Changed in Light Pre-Holiday Trade -- Market Talk

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

9.28% augšup

Prognoze 12 mēnešiem

Vidējais 20.5 USD  9.28%

Augstākais 25 USD

Zemākais 16 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

5 ratings

2

Pirkt

3

Turēt

0

Pārdot

Noskaņojums

By Acuity

156 / 374 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat